SXTP
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock is fundamentally undervalued in a negative sense; it has no positive book value to support the price.
- Negative P/B ratio
- No P/E or Graham Number available due to losses
Growth in revenue is overshadowed by the scale of losses.
- Revenue growth is accelerating Q/Q
- Earnings growth is volatile and deeply negative
- Unsustainable burn rate
Historical price action is a total wipeout of shareholder value.
- 5Y change of -99.8%
- Consistent failure to meet earnings estimates
The F-Score confirms the company is in the weakest possible health category.
- Low absolute debt
- Piotroski F-Score 1/9
- Negative ROE of -200.92%
Dividend strength is 0/100.
- No dividend paid
- No capacity to pay dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SXTP and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
Primary
|
-99.8% | -99.8% | -85.4% | -69.3% | -5.6% | -5.2% |
|
INBS
Intelligent Bio Solutions Inc.
Peer
|
-100.0% | -99.3% | -79.8% | -77.0% | -39.7% | -10.6% |
|
SBFM
Sunshine Biopharma, Inc.
Peer
|
-100.0% | -99.9% | -17.6% | -50.7% | -6.4% | +3.2% |
|
JAGX
Jaguar Health, Inc.
Peer
|
-100.0% | -100.0% | -92.8% | -82.2% | -34.7% | -7.8% |
|
CLGN
CollPlant Biotechnologies Ltd.
Peer
|
-97.4% | -95.1% | -85.0% | -83.7% | -43.0% | -33.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
BEARISH | $4.85M | - | -200.9% | -% | $1.84 | |
|
INBS
Intelligent Bio Solutions Inc.
|
BEARISH | $4.92M | - | -150.2% | -% | $2.46 | Compare |
|
SBFM
Sunshine Biopharma, Inc.
|
BEARISH | $5.05M | - | -25.7% | -16.5% | $1.03 | Compare |
|
JAGX
Jaguar Health, Inc.
|
BEARISH | $4.58M | - | -% | -% | $0.37 | Compare |
|
CLGN
CollPlant Biotechnologies Ltd.
|
BEARISH | $5.18M | - | -117.6% | -% | $0.36 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | DOW GEOFFREY S | Chief Executive Officer | Purchase | 9,670 | $7,759 |
| 2025-12-11 | DOW GEOFFREY S | Chief Executive Officer | Purchase | 12,963 | $12,204 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SXTP from our newsroom.